Damages Back In Play In Pfizer Patent Suit

Law360, New York (September 26, 2007, 12:00 AM EDT) -- A federal judge has reconsidered his ruling in a patent infringement dispute over Pfizer Inc.'s Accupril, deciding to put some potential damages against defendants Ranbaxy Laboratories Ltd. and Teva Pharmaceuticals USA Inc. back on the table.

Judge Dickinson R. Debevoise on Tuesday vacated his April decision, reneging on his former approval of a defendants' motion for summary judgment. The ruling had limited the amount of damages that Pfizer could get from Ranbaxy or Teva.

Judge Debevoise ruled that the issue should be left up to a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.